Stage Iv Non Small Cell Lung Cancer Nsclc clinical trials

Explore recruiting stage iv non small cell lung cancer nsclc clinical trials.

Recruiting stage iv non small cell lung cancer nsclc studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Stage Iv Non Small Cell Lung Cancer Nsclc trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 3, Randomized Study of Nivolumab plus Ipilimumab in Combination with Chemotherapy vs Chemotherapy alone as First Line Therapy in Stage IV Non-Small Cell Lung Cancer (NSCLC)

Spain, Ireland, Poland, Belgium, France, Germany +1 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

KEYMAKER-U01 Substudy 01G: A Phase 2, Umbrella Study With Rolling Arms of Investigational Agents in Combination With Pembrolizumab With or Without Platinum-based Chemotherapy in Treatment-Naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC)

Greece, Italy, Spain, Hungary, Poland

Therapeutic exploratory (Phase II) EU CTIS Study details

IFCT-1701 DICIPLE A randomized phase 3 trial comparing continuation Nivolumab-Ipilimumab doublet immunotherapy until progression versus observation in treatment-naive patients with stage IV Non-Small Cell Lung Cancer (NSCLC) after Nivolumab-Ipilimumab induction treatment

France

Therapeutic confirmatory (Phase III) EU CTIS Study details

IFCT-1802 SAVIMMUNE A phase II single-arm trial evaluating safety and efficacy of Durvalumab in ECOG Performance Status 2-3, treatment-naive, patients with stage IV Non-Small Cell Lung Cancer (NSCLC) and high PD-L1 tumor expression

France

Therapeutic exploratory (Phase II) EU CTIS Study details

IFCT-2103 DIAL De-escalation Immunotherapy mAintenance duration trial for stage IV Lung cancer patients with disease control after chemo-immunotherapy induction A phase II-III randomized trial evaluating maintenance pembrolizumab (± pemetrexed) until progression versus observation (± pemetrexed) after 6 months of platinum-based doublet chemotherapy plus pembrolizumab induction treatment in patients with stage IV Non-Small Cell Lung Cancer (NSCLC)

France

Phase II and Phase III (Integrated) EU CTIS Study details

I4T-MC-JVCY: A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer

Spain

Therapeutic confirmatory (Phase III) EU CTIS Study details

Stage Iv Non Small Cell Lung Cancer Nsclc trials by city

Stage Iv Non Small Cell Lung Cancer Nsclc in Toronto Stage Iv Non Small Cell Lung Cancer Nsclc in Vancouver Stage Iv Non Small Cell Lung Cancer Nsclc in Montreal Stage Iv Non Small Cell Lung Cancer Nsclc in Calgary Stage Iv Non Small Cell Lung Cancer Nsclc in Edmonton Stage Iv Non Small Cell Lung Cancer Nsclc in Ottawa Stage Iv Non Small Cell Lung Cancer Nsclc in Winnipeg Stage Iv Non Small Cell Lung Cancer Nsclc in Quebec City Stage Iv Non Small Cell Lung Cancer Nsclc in Hamilton Stage Iv Non Small Cell Lung Cancer Nsclc in Kitchener Stage Iv Non Small Cell Lung Cancer Nsclc in London Stage Iv Non Small Cell Lung Cancer Nsclc in Halifax Stage Iv Non Small Cell Lung Cancer Nsclc in New York Stage Iv Non Small Cell Lung Cancer Nsclc in Los Angeles Stage Iv Non Small Cell Lung Cancer Nsclc in Chicago Stage Iv Non Small Cell Lung Cancer Nsclc in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease